A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Ixekizumab (Primary) ; Ustekinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IXORA-S
- Sponsors Eli Lilly
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.
- 23 Dec 2017 This trial was completed in Netherlands according to European Clinical Trials Database.
- 07 Dec 2017 This trial was completed in Belgium (end date: 2017-10-05), according to European Clinical Trials Database record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History